The World Health Organization (WHO) said on Friday (16) that it will evaluate monoclonal antibodies and other antiviral drugs in its test of treatments with the potential to face covid-19, after its study revealed that Gilead’s remdesivir, had no impact on survival rates.
WHO Director-General Tedros Adhanom Ghebreyesus told a news conference that the test called Solidarity will continue, after being launched in March at 500 hospitals in 30 countries to assess the effectiveness of remdesivir and several other drugs in patients with covid-19. .
“The Solidarity test is still recruiting around 2,000 patients every month and will evaluate other treatments, including monoclonal antibodies and new antivirals,” Tedros told a news conference.
The Solidarity test was the focus of a discussion this Friday between WHO and Gilead, the US company that developed the remdesivir drug, which said the findings of the WHO test appeared inconsistent with evidence from other studies.